Review of Prophylactic Anticoagulation Strategies and Outcomes for COVID-19 Patients (Research in Progress) by Galindo, Caleb et al.
Providence St. Joseph Health 
Providence St. Joseph Health Digital Commons 
Providence Pharmacy PGY1 Program at 
Providence Portland and Providence St. Vincent 
Medical Centers 2021 
Providence Pharmacy PGY1 Program at 
Providence Portland and Providence St. Vincent 
Medical Centers 
5-2021 
Review of Prophylactic Anticoagulation Strategies and Outcomes 




Follow this and additional works at: https://digitalcommons.psjhealth.org/oaa_ppmcstvin_21 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Review of Prophylactic Anticoagulation Strategies and 
Outcomes for COVID-19 Patients (Research in Progress)






Incidence of Thromboembolic Events According to Medication and Dosing Strategy
• Information from this study is intended to give insight 
into which anticoagulation strategy is optimal for 
patients diagnosed with COVID-19.
Patient Population
•Total of 229 patients included in analysis
•Average age 62 years, range 18-96
•Exclusion data (18 patients)
•Hx of hemorrhagic stroke, COVID-19 resolved before 
administration of anticoagulant, presenting with a 
bleed, on dual-antiplatelet therapy 
Currently Available Data:
•Significant difference (X2 = 4.009, p = 0.0452) between 
incidence of thromboembolism in standard enoxaparin 
vs intermediate enoxaparin, with greater incidence in 
intermediate group
•Currently no meaningful trends/differences among 
anticoagulants with limited samples (dabigatran, 
fondaparinux, rivaroxaban, warfarin).
•Among dosing strategies with outcomes of interest, 
there appears to be no evidence of increased risk of VTE 
with prophylaxis enoxaparin compared to other dosing 
strategies (though sample sizes for these are small).
•Among dosing strategies with outcomes of interest, 
there appears to be evidence of increased risk of 
bleeding with agents other than prophylaxis enoxaparin 
(apixaban, intermediate enoxaparin, treatment 
enoxaparin) 
Limitations
•This is a snapshot of patients in the beginning of the 
pandemic when clinical guidance on optimal 
anticoagulation strategies was limited and evolving.
•Overall practice and treatment of patients diagnosed 
with COVID-19 has evolved over time and may present 
confounding factors in assessing outcomes.
•This data is limited in capturing overall incidence of VTE 
as it is limited to inpatient data. Incidence of VTE after 
hospitalization is not represented in this data and may 
exhibit differences based on anticoagulation strategy.
•Data collected included patients in all areas of the 
hospital; meaningful difference in acuity of COVID-19 
and effect on VTE/bleeding may be underrepresented in 
this format.
Health & Services
• In March of 2020, the World Health Organization (WHO) 
declared the spread of COVID-19 a global pandemic.
•Though largely considered a respiratory disease, 
research continues to demonstrate additional impacts of 
COVID-19 on other organ systems.2, 3
•A key characteristic of COVID-19 is marked inflammation   
leading to hypercoagulability.2, 3, 6
• Infected patients are at a higher risk of developing 
thromboembolic events (VTE and stroke) compared to 
healthy adults. 2, 3, 6
•Some clinicians have trialed varying anticoagulation 
strategies for patients with COVID-19 based on 
coagulation parameters such as D-dimer.4, 5, 6
•Multiple expert groups have released preliminary 
guidance on anticoagulation strategies for patients with 
COVID-19; however, there is a lack of consensus.1, 4,  5, 6, 7
•Early reports suggested high rates of VTE in patients 
infected with COVID-19, despite standard prophylactic 
doses of anticoagulants.3, 5
Methods
•Study design
•Retrospective review of medical records
•Data represented here is a homogenous sample 
(~50%) of a total of 473 patient records to be 
analyzed
•Inclusion criteria
•Adults aged 18 years or older and active diagnosis of 
COVID-19, hospitalized in one of two institutional 
hospitals in Portland, OR between March 1, 2020  -
October 1, 2020, and receiving anticoagulation
•Exclusion criteria
•Heparin-induced thrombocytopenia in last 100 days, 
stroke within 30 days, history of hemorrhagic stroke, 
gastrointestinal bleed in last 60 days, platelet count < 
25,000 platelets/microliter, active bleeding upon 
admission, patients on dual-antiplatelet therapy, 
patients with brain/spinal/ophthalmologic surgery in 
last 30 days
•Primary outcome
•Evaluate inpatient prophylactic anticoagulation 
strategies and assess outcomes regarding efficacy in 
the prevention of thromboembolic events
•Secondary outcomes
•Evaluate safety (presence of bleeding possibly 
requiring medical intervention) of varying dosing 
strategies and choice of prophylactic anticoagulation
Definitions
•Standard dosing – administration of anticoagulant drugs 
for the primary prevention of VTE
• Intermediate dosing – off-label anticoagulant dose 
greater than standard dosing but lesser than treatment 
dosing, intended for primary prevention of VTE
•Treatment dosing – anticoagulation dosing strategy for 
the treatment of VTE(s) already present
•Bleeding A – overt bleeding requiring medical 
intervention and interruption/delayed dosing of 
anticoagulation
•Bleeding B – bleeding possibly requiring medical 
intervention but not requiring interruption or temporary 
interruption/delayed dosing of anticoagulation
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•This data is in line with the 2021 ASH recommendation 
for standard enoxaparin over intermediate/therapeutic 
intensity anticoagulation in COVID-19 patients without 
DVT/PE1
•Further analysis into biomarkers, particularly D-dimer, 
may be insightful for patients receiving intermediate 
dosing enoxaparin.
•Analysis of demographic trends in patients with 
outcomes of interest may provide valuable insight. 
•Statistical analysis pending larger sample is in progress.
•Additional research into current COVID-19 patients to 
account for changes in clinical practice and new strains 
of the virus is warranted.
Incidence of  Bleeding According to Medication and  Dosing Strategy
Total Incidence of Thromboembolic Events and Bleeding
Thromboembolic Events According to Medication and Dosing Strategy
Agent Thromboembolism Bleeding A Bleeding B
Apixaban (n=17) 2 (11.8%) 3 (17.6%) 
Dabigatran (n=1)
Fondaparinux (n=3) 1 (33.3%)
Heparin SQ (n=17) 1 (5.9%)
Intermediate enoxaparin (n=33) 4 (12.1%) 5 (15.1%) 4 (12.1%)
Standard enoxaparin (n=142) 5 (3.5%) 1 (0.7%) 10 (7%)
Rivaroxaban (n=1)
Treatment enoxaparin (n=4) 1 (25%)
Warfarin (n=3) 1 (33.3%)
Total (n=229) 12 (5.2%) 9 (4.1%) 17 (7.4%)
Agent Stroke PE DVT + PE DVT Total
Apixaban (n=17) 1 1 2
Fondaparinux (n=3) 1 1
Intermediate enoxaparin (n=33) 1 3 4
Standard enoxaparin (n=142) 2 1 2 5
Total (n=229) 1 2 3 6 12
